EpimAb Biotherapeutics and Almirall announce bispecific antibody license agreement.
EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies, and Almirall, a global biopharmaceutical company focused on medical dermatology, announced a license agreement on the development of bispecific antibodies for up to three undisclosed target pairs.
In exchange, EpimAb is eligible to receive milestone payments totaling up to $210 million contingent upon launch and commercial success of multiple products, plus royalties on net sales for any commercialized product. Further financial details were not disclosed.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
